Original Paper

Regulation of the Voltage Gated K⁺ Channel K_{v1.3} by Recombinant Human Klotho Protein

Ahmad Almilaji^a Sabina Honisch^a Guilai Liu^a Bernat Elvira^a
Sumant Singh Ajay^a Zohreh Hosseinzadeh^a Musaab Ahmed^a Carlos Munoz^b
Mentor Sopjani^c Florian Lang^a

^aDepartment of Physiology, University of Tübingen, Tübingen, Germany; ^bInstitute of Physiology and Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland;

^cFaculty of Medicine, University of Prishtina, Prishtina, Kosova

Key Words

Alpha Klotho protein • Recombinant human Klotho protein • K_{v1.3} channel • *Xenopus* oocytes • Jcam cells

Abstract

Background/Aims: Klotho, a protein mainly produced in the kidney and released into circulating blood, contributes to the negative regulation of 1,25(OH)₂D₃ formation and is thus a powerful regulator of mineral metabolism. As β-glucuronidase, alpha Klotho protein further regulates the stability of several carriers and channels in the plasma membrane and thus regulates channel and transporter activity. Accordingly, alpha Klotho protein participates in the regulation of diverse functions seemingly unrelated to mineral metabolism including lymphocyte function. The present study explored the impact of alpha Klotho protein on the voltage gated K⁺ channel K_{v1.3}. **Methods:** cRNA encoding K_{v1.3} (KCNA3) was injected into *Xenopus* oocytes and depolarization induced outward current in K_{v1.3} expressing *Xenopus* oocytes determined utilizing dual electrode voltage clamp. Experiments were performed without or with prior treatment with recombinant human Klotho protein (50 ng/ml, 24 hours) in the absence or presence of a β-glucuronidase inhibitor D-saccharic acid-1,4-lactone (DSAL, 10 μM). Moreover, the voltage gated K⁺ current was determined in Jcam lymphoma cells by whole cell patch clamp following 24 hours incubation without or with recombinant human Klotho protein (50 ng/ml, 24 hours). K_{v1.3} protein abundance in Jcam cells was determined utilizing fluorescent antibodies in flow cytometry. **Results:** In K_{v1.3} expressing *Xenopus* oocytes the K_{v1.3} currents and the protein abundance of K_{v1.3} were both significantly enhanced after

A. Almilajia and S. Honisch contributed equally and thus share first authorship

treatment with recombinant human Klotho protein (50 ng/ml, 24 hours), an effect reversed by presence of DSAL. Moreover, treatment with recombinant human Klotho protein increased K_v currents and $K_{v1.3}$ protein abundance in Jcam cells. **Conclusion:** Alpha Klotho protein enhances $K_{v1.3}$ channel abundance and $K_{v1.3}$ currents in the plasma membrane, an effect depending on its β -glucuronidase activity.

Copyright © 2014 S. Karger AG, Basel

Introduction

Klotho, a protein expressed in diverse tissues including kidney, parathyroid glands, and choroid plexus [1, 2], is a major determinant of aging and life span [3, 4]. Klotho deficiency results in accelerated aging with early death [4] and Klotho overexpression enhances the life span [3, 4]. The extracellular domain of Klotho may function as β -glucuronidase and hormone [5-7]. Klotho is required for the inhibitory effect of FGF23 on 25-hydroxyvitamin D-1 α -hydroxylase and thus formation of 1,25-dihydroxyvitamin D (1,25(OH) $_2$ D $_3$) [2, 3, 8-10], the active form of vitamin D [11], which is generated mainly in kidney [12], but may be produced in addition by B cells [13], dendritic cells and macrophages [14, 15]. 1,25(OH) $_2$ D $_3$ in turn stimulates the expression of FGF23 and Klotho [8, 16, 17]. 1,25(OH) $_2$ D $_3$ is further a powerful stimulator of intestinal and renal Ca $^{2+}$ and phosphate transport [11, 18]. Klotho deficiency increases plasma 1,25(OH) $_2$ D $_3$, Ca $^{2+}$ and phosphate [18, 19] concentration, resulting in vascular calcification [20], growth deficit [2] and rapid aging [2, 9, 10]. Klotho insufficiency further leads to a wide variety of disorders including hypoglycemia, hearing loss, cardiac arrhythmia, sudden cardiac death, and compromised immune response [1, 21, 22].

Klotho has been shown to modify the activity of several channels and transport proteins including Ca $^{2+}$ channels [23], renal outer medullary K $^{+}$ channels [24], Na $^{+}$, phosphate cotransport [25, 26] and Na $^{+}$ /K $^{+}$ ATPase [27]. It is at least in part effective as β -glucuronidase [5-7].

The present study explored whether Klotho modifies the function of voltage gated K $^{+}$ channel $K_{v1.3}$ (KCNA3), a channel expressed in many tissues and participating in the regulation of a wide variety of cellular functions, including excitability [28-31], cell proliferation [32], apoptosis [33], immune response [34, 35], insulin sensitivity [36], and platelet function [37]. Cells expressing $K_{v1.3}$ include Jurkat and Jcam lymphoma cells, where the channels participate in the regulation of apoptosis [33].

$K_{v1.3}$ has been expressed in *Xenopus* oocytes with or without subsequent treatment with human recombinant Klotho protein in the presence or absence of the β -glucuronidase inhibitor DSAL (D-saccharic acid-1,4-lactone). The $K_{v1.3}$ activity was determined by dual electrode voltage clamp and $K_{v1.3}$ protein abundance at the cell membrane quantified by chemiluminescence. Moreover, voltage gated $K_{v1.3}$ currents and $K_{v1.3}$ protein abundance were determined in Jcam cells without or with prior exposure to recombinant human alpha Klotho protein.

Materials and Methods

Ethics Statement

Xenopus oocytes were explanted from adult *Xenopus Laevis* (NASCO). *Xenopus Laevis* frogs were anaesthetized by a 0.1% Tricaine solution. After confirmation of anaesthesia and disinfection of the skin, a small abdominal incision was made and oocytes were removed, followed by closure of the skin by sutures. All animal experiments were conducted in accordance with the Helsinki Declaration of 1975 and according to the German law for the welfare of animals and the surgical procedures on the adult *Xenopus laevis* were reviewed and approved by the respective government authority of the state Baden-Württemberg (Regierungspräsidium Tübingen) prior to the start of the study (Anzeige für Organentnahme nach §6).

Constructs

For generation of cRNA, a construct was used encoding wild-type mouse $K_{v1.3}$ (KCNA3) [38]. The construct was used for the generation of cRNA as described previously [39, 40].

Voltage clamp in *Xenopus* oocytes

Xenopus oocytes were prepared as previously described [41, 42]. cRNA encoding $K_{v1.3}$ (2.5 ng) was injected on the same or the second day of *Xenopus* oocytes preparation [43, 44]. All experiments were performed at room temperature 3 days after cRNA injection [45, 46]. The oocytes were maintained at 17°C in ND96 solution containing: 88.5 mM NaCl, 2 mM KCl, 1 mM $MgCl_2$, 1.8 mM $CaCl_2$, 5 mM HEPES. Tetracycline (50 mg/l), Ciprofloxacin (1.6 mg/l), Refobacin (100 mg/l) and Theophylline (90 mg/l) as well as sodium pyruvate (5 mM) were added to the ND96, and pH was adjusted to 7.5 by addition of NaOH. The control superfusate (ND96) contained 96 mM NaCl, 2 mM KCl, 1.8 mM $CaCl_2$, 1 mM $MgCl_2$ and 5 mM HEPES; pH was adjusted to 7.4 by addition of NaOH. Where indicated, recombinant human Klotho protein (10, 30 or 50 ng/ml, 5334-KL-R&D Systems) was added for 6, 12 or 24 hours before voltage clamp measurements (66, 60 and 48 hours respectively after injection of cRNA encoding $K_{v1.3}$) and D-saccharic acid 1,4-lactone monohydrate (DSAL, 10 μ M, Sigma) was added for 24 hours before voltage clamp measurements. In dual electrode voltage-clamp experiments $K_{v1.3}$ channel currents were elicited every 15 second with 2 second depolarizing pulses up to +50 mV applied from a holding potential of -100 mV. Pulses were applied in 10 mV increments. The data were filtered at 2 kHz and recorded with a Digidata 1322A A/D-D/A converter and ClampexV.9.2 software for data acquisition (Axon Instruments) [47, 48]. The analysis of the data was performed with Clampfit 9.2 (Axon Instruments) software [49, 50].

Chemiluminescence

Chemiluminescence was employed for detection of $K_{v1.3}$ cell surface expression in oocytes, which are too large to be analysed by flow cytometry. Oocytes were first incubated with primary polyclonal rabbit anti- $K_{v1.3}$ antibody (extracellular) (1:200, Alomone Labs) and subsequently with secondary, HRP-conjugated anti-rabbit IgG antibody (1:2500, Cell Signaling). Individual oocytes were placed in 96 well plates with 20 μ l of SuperSignal ELISA Femto Maximum Sensitivity Substrate (Pierce) and chemiluminescence of single oocytes was quantified in a luminometer (Walter Wallac 2 plate reader, Perkin Elmer) by integrating the signal over a period of 1 sec [51]. Results display normalized relative light units. Integrity of the measured oocytes was assessed by visual control after the measurement to avoid unspecific light signals from the cytosol [52]. Where indicated, recombinant human Klotho protein (50 ng/ml, 5334-KL-R&D Systems) was added for 24 hours before chemiluminescence measurements (48 hours after injection of cRNA encoding $K_{v1.3}$).

Culture of Jcam cells

Jcam cells were grown in DMEM supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine (Gibco-Invitrogen, Karlsruhe, Germany).

Patch clamp

Patch clamp experiments have been performed at room temperature in voltage-clamp, fast-whole-cell mode as described previously [53-55]. The cells were continuously superfused through a flow system inserted into the dish. Borosilicate glass pipettes (2-5 M Ω tip resistance; Harvard Apparatus, Kent, UK) manufactured by a microprocessor-driven DMZ puller (Zeitz, Augsburg, Germany) were used in combination with a MS314 electrical micromanipulator (MW, Märzhäuser, Wetzlar, Germany) [56]. The currents were recorded by an EPC-9 amplifier (Heka, Lambrecht, Germany) using Pulse software (Heka) and an ITC-16 Interface (Instrutech, Port Washington, N.Y., USA). Whole-cell currents were elicited by 200 msec square wave voltage pulses from -100 to +100 mV in 20 mV steps delivered at 15 second intervals from a holding potential of -60 mV or by 200 millisecond square wave voltage pulses from -60 to +20 mV in 5 mV steps delivered at 15 second intervals from a holding potential of -60 mV. The currents were recorded with an acquisition frequency of 10 kHz and 3 kHz low-pass filtered. Since the time constant of activation decreased with the applied depolarizing voltage step and inactivation occurred especially during strong depolarization, the current was analyzed at its maximal amplitude value (peak current).

The Jcam cells were superfused with a bath solution containing (in mmol/l): 145 NaCl, 5 KCl, 2 $MgCl_2$, 2 $CaCl_2$, 5 glucose and 10 HEPES, pH 7.4 (NaOH). The patch clamp pipettes were filled with an internal solution

containing (in mmol/l): 80 KCl, 60 K⁺-gluconate, 1 MgCl₂, 1 Mg-ATP, 1 EGTA, 10 HEPES; pH was adjusted to 7.2 (KOH). Where indicated, recombinant human Klotho protein (50 ng/ml, 5334-KL-R&D Systems) was added 24 hours before patch clamp measurements.

The offset potentials between both electrodes were zeroed before sealing. The potentials were corrected for liquid junction potentials as estimated according to [57, 58]. The original whole-cell current traces are depicted and currents of the individual voltage square pulses are superimposed. The applied voltages refer to the cytoplasmic face of the membrane with respect to the extracellular space. The outward currents, defined as flow of positive charge from the cytoplasmic to the extracellular membrane face, are positive currents and depicted as outward deflections of the original current traces.

Flow cytometry

For measurement of K_{v1.3} protein abundance, 5 × 10⁵ Jcam cells were incubated without or with klotho protein [50 ng/ml], washed twice with PBS (Gibco, Invitrogen) and fixed for 5 minutes with 4% paraformaldehyde on ice. After additional two washes with PBS and permeabilization with 0.1% Triton X-100 for 2 mins cells were incubated for 1 h at 37°C with the primary K_{v1.3} antibody (1:250, Alomone Labs, Israel) at 37°C. For detection the cells were washed twice with PBS-BSA (0.1%) and stained for 30 min at 37°C with CF™ 488A-labeled goat anti-rabbit secondary antibody (1: 250, Sigma-Aldrich, USA). Unbound secondary antibody was removed by repeated washing with PBS-BSA and the samples were analyzed by flow cytometry (BD FACS Calibur, BD Biosciences, USA) for median fluorescence intensity at excitation on 488 nm and emission on 530 nm.

Statistics

Data are provided as means ± SEM, *n* represents the number of independent experiments. All oocyte experiments were repeated with at least 3 batches of oocytes; in all repetitions qualitatively similar data were obtained. All data were tested for significance using ANOVA followed by posthoc analysis or unpaired t-test, where appropriate. Only results with *p* < 0.05 were considered statistically significant.

Results

The present study explored the effect of recombinant human Klotho protein on the voltage gated K⁺ channel K_{v1.3} (KCNA3). To this end, cRNA encoding K_{v1.3} was injected in *Xenopus* oocytes and depolarization induced outward currents were recorded by dual electrode voltage clamp. The amplitude of the peak outward currents was taken as a measure of the voltage gated K⁺ channel K_{v1.3} conductance in *Xenopus* oocytes. As illustrated in Fig. 1-A,B, no appreciable outward K_{v1.3}-like currents were measured in *Xenopus* oocytes injected only with water. Thus, *Xenopus* oocytes do not express appreciable endogenous K_{v1.3}-like channels. In contrast, depolarization of *Xenopus* oocytes injected with cRNA encoding K_{v1.3} was followed by a rapidly inactivating outward current typical for K_{v1.3} channel. Further experiments explored whether the effect of recombinant human Klotho protein on K_{v1.3} currents resulted from an effect of Klotho on K_{v1.3} protein abundance in the cell membrane. The protein abundance was quantified by chemiluminescence. As shown in Fig. 1C, the cell surface expression of the K_{v1.3} channel protein in *Xenopus* oocytes was indeed significantly increased by pretreatment with the recombinant human Klotho protein.

As illustrated in Fig. 2, the amplitude of the depolarization induced peak currents was significantly enhanced by a 24 hours pretreatment with recombinant human Klotho protein (50 ng/ml) prior to voltage clamp recording. The effect of recombinant human Klotho protein (50 ng/ml) on the depolarization induced outward current amplitude in K_{v1.3} expressing *Xenopus* oocytes was time-dependent and reached statistical significance after 12 hours of incubation without reaching a plateau (Fig. 2). Fitting the mean peak current and the time course till 12 hours to Boltzman function yielded a half-life time *t*_{1/2} of 3.8 hours.

In theory alpha Klotho protein could have been effective as beta-glucuronidase. In order to test whether recombinant human Klotho protein enhanced K_{v1.3} currents by exerting beta-glucuronidase activity, the effect of recombinant human Klotho protein (50 ng/ml,

Fig. 1. Effect of recombinant human Klotho protein on $K_{v1.3}$ peak current amplitude in $K_{v1.3}$ expressing *Xenopus* oocytes and on $K_{v1.3}$ -HA plasma membrane abundance in $K_{v1.3}$ -HA expressing *Xenopus* oocytes. A. Original tracings demonstrating outward $K_{v1.3}$ currents activated by depolarization from -80 to +50 mV in 20 second increments of 10 mV steps from a holding potential of -100 mV in *Xenopus* oocytes injected with water (i), or injected with cRNA encoding $K_{v1.3}$ without (ii) or with (iii) 24 hours treatment with recombinant human Klotho protein (50 ng/ml) prior to measurement. B. Arithmetic means $\pm$ SEM ($n = 6-42$) of the normalized depolarization-induced $K_{v1.3}$ peak current as a function of voltage in *Xenopus* oocytes injected with water (grey triangles), or with cRNA encoding $K_{v1.3}$ without (white circles) or with (black circles) 24 hours treatment with recombinant human Klotho protein (50 ng/ml) prior to measurement. Peak currents are normalized to the mean peak current at +50 mV in *Xenopus* oocytes injected with cRNA encoding $K_{v1.3}$ and not treated with recombinant human Klotho protein prior to measurement. *** ($p < 0.001$) indicates statistically significant difference from *Xenopus* oocytes injected with cRNA encoding $K_{v1.3}$ and not treated with recombinant human Klotho protein prior to measurement. C. Arithmetic means $\pm$ SEM ($n = 64-67$) of the $K_{v1.3}$ protein abundance in the plasma membrane of *Xenopus* oocytes injected with water (dotted bar), or injected with cRNA encoding $K_{v1.3}$ without (white bar) or with (black bar) 24 hours treatment with recombinant human Klotho protein (50 ng/ml) prior to measurement. ** ($p < 0.01$) indicates statistically significant difference from the protein abundance of $K_{v1.3}$ in untreated *Xenopus* oocytes injected with cRNA encoding $K_{v1.3}$.

24 hours) on the depolarization induced outward current in $K_{v1.3}$ expressing *Xenopus* oocytes was measured using dual electrode voltage clamp in the presence and absence of 10 μ M of D-saccharic acid-1,4-lactone (DSAL), which is known to inhibit the beta glucuronidase activity of Klotho protein. As illustrated in Fig. 3, the effect of recombinant human Klotho protein (50 ng/ml, 24 hours) on the depolarization induced outward current in $K_{v1.3}$ expressing *Xenopus* oocytes was virtually abrogated in the presence of DSAL (10 μ M).

In order to test, whether recombinant human Klotho protein is similarly effective in $K_{v1.3}$ expressing mammalian cells, a further series of experiments was performed in Jcam lymphoma cells. According to flow cytometry, Jcam cells expressed $K_{v1.3}$ (Fig. 4). The $K_{v1.3}$ protein abundance was significantly increased by treatment of Jcam lymphoma cells with recombinant human Klotho protein (50 ng/ml) for 24 hours (Fig. 4).

Fig. 2. Time course of the increase in $K_{v1.3}$ peak current amplitude following treatment with recombinant human Klotho protein in $K_{v1.3}$ expressing *Xenopus* oocytes. A. Original tracings demonstrating outward $K_{v1.3}$ currents activated by depolarization from -80 to +50 mV in 20 second increments of 10 mV steps from a holding potential of -100 mV in *Xenopus* oocytes injected with water (i), or injected with cRNA encoding $K_{v1.3}$ without (ii) or with (iii) 24 hours treatment with recombinant human Klotho protein (50 ng/ml) prior to measurement. B. Arithmetic means $\pm$ SEM (n = 8-17) of the normalized depolarization-induced $K_{v1.3}$ peak current at +50 mV in *Xenopus* oocytes injected with cRNA encoding

$K_{v1.3}$ without (white bar) or with (black bars) 6, 12, or 24 hours treatment with recombinant human Klotho protein (50 ng/ml) prior to measurement. Peak currents are normalized to the mean peak current at +50 mV in *Xenopus* oocytes injected with cRNA encoding $K_{v1.3}$ and untreated with recombinant human Klotho protein prior to measurement. * (p<0.05), *** (p<0.001) indicates statistically significant difference from *Xenopus* oocytes injected with cRNA encoding $K_{v1.3}$ and not treated with recombinant human Klotho protein prior to measurement.

The voltage gated K^+ currents in Jcam lymphoma cells are illustrated in Fig. 5. Treatment of those cells with recombinant human Klotho protein (50 ng/ml) for 24 hours was followed by a significant increase of rapidly inactivating outward current typical for $K_{v1.3}$ channels [59]. The mean peak current density was increased from 51 ± 6 pA/pF (at +100 mV; n = 20) to 88 ± 13 pA/pF (at +100 mV; n = 21) following a 24 hours treatment of Jcam cells with recombinant human Klotho protein. Exposure to recombinant human Klotho protein increased the peak current density without appreciably affecting the other biophysical properties of the voltage gated K^+ currents in Jcam cells. Fitting the normalized conductance to Boltzman equation showed no difference in the half maximal activation voltage $V_{1/2}$ and the slope factor K before ($V_{1/2} = -38.7 \pm 1.9$ mV, $K_{\text{slope factor}} = 2.9 \pm 0.7$, n=14) and after ($V_{1/2} = -39.6 \pm 1.5$ mV, $K_{\text{slope factor}} = 2.1 \pm 0.5$, n=16) 24 hours treatment of Jcam cells with recombinant human Klotho protein (Fig.6). The activation time constants (τ_{act}) were calculated by fitting a single exponential function to the rising phase of currents at voltages from +20 to +100 mV. The mean activation time constant (τ_{act}) was not significantly different without (n = 11) or with (n = 12) a prior 24 hours exposure to recombinant human Klotho protein (Fig.6). The inactivation time constants ($\tau_{\text{inactivation}}$) were calculated by fitting single exponential function to the decaying phase of currents at voltages from +60 to +100 mV. The inactivation time constant ($\tau_{\text{inactivation}}$) was slightly different at +91 mV and at +71 mV between cells with or without prior Klotho treatment, a difference, however, not reaching

Fig. 3. Effect of recombinant human Klotho protein on $K_{v1.3}$ peak current amplitude in absence and presence of β -glucuronidase inhibitor (DSAL) in $K_{v1.3}$ expressing *Xenopus* oocytes. A. Original tracings demonstrating outward $K_{v1.3}$ currents activated by depolarization from -80 to +50 mV in 20 second increments of 10 mV steps from a holding potential of -100 mV in *Xenopus* oocytes injected with cRNA encoding $K_{v1.3}$ without (i) or following 24 hours pretreatment with recombinant human Klotho protein (50 ng/ml) in the absence (ii) and presence (iii) of D-saccharic acid-1,4-lactone, DSAL (10 μ M). B. Arithmetic means $\pm$ SEM (n = 39-53) of the normalized depolarization-induced $K_{v1.3}$ peak current as a function of voltage in *Xenopus* oocytes injected with cRNA encoding $K_{v1.3}$ without (white circles) or following 24 hours pretreatment with recombinant human Klotho protein (50 ng/ml) in the absence (black circles) and presence (grey triangles) of D-saccharic acid-1,4-lactone, DSAL (10 μ M). *** (p<0.001) indicates statistically significant difference from not treated $K_{v1.3}$ expressing *Xenopus* oocytes. ### (p<0.001) indicates statistically significant difference from *Xenopus* oocytes injected with cRNA encoding $K_{v1.3}$ and treated with recombinant human Klotho protein for 24 hours in the absence of D-saccharic acid-1,4-lactone, DSAL (10 μ M). C. Arithmetic means $\pm$ SEM (n = 39-53) of the normalized depolarization-induced $K_{v1.3}$ peak current at +50 mV in *Xenopus* oocytes injected with cRNA encoding $K_{v1.3}$ without (white bar) or following 24 hours pretreatment with recombinant human Klotho protein (50 ng/ml) in the absence (black bar) and presence (grey bar) of D-saccharic acid-1,4-lactone, DSAL (10 μ M). *** (p<0.001) indicates statistically significant difference of from untreated $K_{v1.3}$ expressing *Xenopus* oocytes. ### (p<0.001) indicates statistically significant difference from *Xenopus* oocytes injected with cRNA encoding $K_{v1.3}$ and treated with recombinant human Klotho protein for 24 hours in the absence of D-saccharic acid-1,4-lactone, DSAL (10 μ M).

Fig. 4. $K_{v1.3}$ protein abundance in Jcam cells. Arithmetic means $\pm$ SEM (n = 4) of $K_{v1.3}$ protein abundance in Jcam cells without (white bar) and with (black bars) prior treatment with Klotho (50 ng/ml) protein for 24 or 48 hours.

statistical significance. The inactivation time constant at +50 mV was significantly (p<0.01) larger in Jcam cells treated with recombinant human Klotho protein ($\tau_{inact} = 145.9 \pm 17.55$ msec, n= 21) than in not treated Jcam cells ($\tau_{inact} = 92.6 \pm 7.9$ msec, n= 20) (Fig.6). The delayed inactivation after 24 hours pre-treatment with recombi-

Fig. 5. Effect of recombinant human Klotho protein on voltage-gated K⁺ channel activity in Jcam T cells. A. Representative tracings demonstrating whole cell Kv currents in Jcam T cells cultured under control conditions (control) or following 24 hour treatment of the cells with 50 ng/ml recombinant human Klotho protein prior to patch clamp recording. The currents were recorded from cells with similar capacitance elicited by 200 ms depolarizing pulses ranging from -100 to +100 mV in 20 mV and 15 s increments from a holding potential of -60 mV. B. Mean current-voltage (I-V) relationships ($\pm$ SE, $n = 20-21$) of K_v peak current density in Jcam T cells cultured under control conditions (○) or following 24 hour treatment of the cells with 50 ng/ml recombinant human Klotho

protein prior to patch clamp recording (●). C. Arithmetic means $\pm$ SEM ($n = 12-24$) of whole cell K_v currents in Jcam T cells cultured under control conditions (white bar) and following 24 hour treatment of the cells with 1-50 ng/ml recombinant human Klotho protein (black bars) prior to patch clamp recording. The currents were recorded from the cells with similar capacitance elicited by 200-ms depolarizing pulses ranging from -100 to +100 mV in 20 mV and 15 s increments from a holding potential of -60 mV.

nant human Klotho protein could be explained by the increased protein abundance of K_{v1.3} in the plasma membrane, which has previously been shown to slow down the channel inactivation kinetics [60].

Discussion

The present study reveals a novel function of Klotho, i.e. the up-regulation of the voltage gated K⁺ channel K_{v1.3} (KCNA3). Apparently Klotho increases the K_{v1.3} channel protein abundance in the cell membrane without appreciably affecting other properties of the channel. The effect of Klotho is reversed by β -glucuronidase inhibitor DSAL and is thus most likely due to the enzyme activity of the Klotho protein. The present observations reveal that K_{v1.3} channel activity is affected by both Klotho expression and exposure of the channels to soluble Klotho. The transmembrane Klotho protein serves as a co-receptor for FGF23 and is required for the inhibitory effect of FGF23 on the 25(OH) vitamin D 1 α hydroxylase [61].

Fig. 6. Effect of recombinant human Klotho protein on biophysical properties of voltage-gated K^+ channels in Jcam T cells. **A.** Representative tracings demonstrating whole cell K_v currents in Jcam T cells cultured under control conditions (control) and following 24 hour treatment of the cells with 50 ng/ml recombinant human Klotho protein prior to patch clamp recording. The currents were recorded from the cells with similar capacitance elicited by 200-ms depolarizing pulses ranging from -60 to $+20$ mV in 5 mV and 15 s increments from a holding potential of -60 mV. **B.** Normalized conductance-voltage (G - V) relationship ($n = 14$ – 16) of K_v peak currents in Jcam T cells cultured under control conditions (○) or following 24 hour treatment of the cells with 50 ng/ml recombinant human Klotho protein prior to patch clamp recording (●). Conductance was normalized to the maximal conductance of K_v peak currents in each group, plotted to the voltage according to Boltzman equation, $V_{1/2}$ and slope factor K were deduced accordingly. The liquid junction potential ΔE between the pipette and the bath solutions was estimated and V corrected accordingly. **C.** Recombinant human Klotho protein does not affect onset of activation of K_v currents in Jcam T cells. Activation time constants (τ activation) were determined by fitting single exponential function to the rising phase of currents at voltages from $+20$ to $+100$ mV of control cells ($n = 11$) and cells pretreated with recombinant human Klotho protein (50 ng/ml, 24 hour, $n = 12$). **D.** Recombinant human Klotho protein affects onset of inactivation of K_v currents in Jcam T cells. Inactivation time constants (τ inactivation) were determined by fitting single exponential function to the decaying phase of currents at voltages from $+60$ to $+100$ mV of control cells ($n = 20$) and cells pretreated with recombinant human Klotho protein (50 ng/ml, 24 hour, $n = 21$). The liquid junction potential ΔE between the pipette and the bath solutions was estimated and V corrected accordingly. *,** indicates statistically significant ($P < 0.05$, 0.01) difference from Jcam T cells cultured under control conditions (control) according to Student's t -test analysis.

The extracellular domain of Klotho may be cleaved off and function as β -glucuronidase and hormone [5-7]. Klotho is released into circulating blood, urine and cerebrospinal fluid and may influence a multitude of functions including transport, energy metabolism, oxidative stress, and hormone release [61].

Klotho has previously been shown to affect a variety of further channels, such as the epithelial Ca^{2+} channels TRPV5 [62-66] and TRPV6 [66], as well as the K^+ channels ROMK [24, 62], KCNQ1/KCNE1 [67] and hERG [68]. Klotho apparently does not appreciably affect the channels TRPV4 [66] or TRPM6 [66]. As shown for TRPV5, Klotho removes alpha2,6-linked sialic acids, which in turn fosters cell surface retention of the channels [63].

Klotho further participates in the regulation of carriers, such as the excitatory amino acid transporters EAAT 3 and EAAT4 [54] and the phosphate transporters NaPi-IIa and NaPi-IIb [25]. Moreover, Klotho up-regulates the Na^+/K^+ ATPase [27]. Klotho sensitive regulation of the excitatory amino acid transporters was also reversed by the β -glucuronidase inhibitor DSAL [54].

Klotho may, however, affect channels by other mechanisms. Klotho down-regulates the endothelial Ca^{2+} channel 1 (TRPC-1) by fostering VEGF-mediated internalization of the VEGFR-2/TRPC-1 complex [69]. Klotho may further affect channel and transporter activity by its involvement in the down-regulation of $1,25(\text{OH})_2\text{D}_3$ formation. In *kl/kl* mice the unrestrained $1,25(\text{OH})_2\text{D}_3$ formation leads to excessive plasma levels of $1,25(\text{OH})_2\text{D}_3$ [8], which in turn directly or indirectly affects several channels, transporters and the Na^+/K^+ ATPase [70-77]. The excessive formation of $1,25(\text{OH})_2\text{D}_3$ in Klotho deficient animals leads, for instance, to decreased activity of the transcription factor NF κ B with subsequent down-regulation of several NF κ B sensitive genes including the Ca^{2+} release activated Ca^{2+} channel Orai1 [78]. Altered channel activity and transport in Klotho deficient animals thus does not only reflect direct effects of Klotho on the respective channel or transporter proteins, but as well the direct and indirect impact of excessive $1,25(\text{OH})_2\text{D}_3$ formation.

In view of the Klotho sensitivity of $\text{K}_{\text{v}1.3}$ protein abundance in the lymphocyte cell membrane, Klotho is expected to modify the immune response. $\text{K}_{\text{v}1.3}$ channels participate in the regulation of the Ca^{2+} influx and short-term activation of lymphocytes [79, 80] and are thus decisive for the immune response [34, 35]. The Klotho sensitivity of lymphocyte $\text{K}_{\text{v}1.3}$ channels may thus well contribute to the known impact of Klotho on the immune system [22]. The concentration of recombinant Klotho employed was higher than the plasma concentrations of approximately 0.5 ng/ml in healthy individuals [81, 82]. On the other hand, the *in vivo* exposure time to plasma klotho is by far longer. Moreover, local concentrations of Klotho may be higher than the plasma concentration. Nevertheless, the quantitative impact of normal plasma klotho concentrations on lymphocyte $\text{K}_{\text{v}1.3}$ channel activity and function cannot be safely predicted from the present observations.

$\text{K}_{\text{v}1.3}$ channels are expressed in many further cell types and participate in the regulation of a wide variety of cellular functions, including excitability [28-31], cell proliferation [32], apoptosis [33], insulin sensitivity [36], and platelet function [37]. Future studies will be required to define the direct or indirect influence of the Klotho protein on those functions.

Conclusion

The present observations reveal that Klotho up-regulates surface protein abundance and activity of the voltage gated K^+ channel $\text{K}_{\text{v}1.3}$ (KCNA3) and may thus participate in the regulation of $\text{K}_{\text{v}1.3}$ dependent cellular functions.

Disclosure Statement

The authors of this manuscript state that they do not have any conflict of interests and nothing to disclose.

Acknowledgements

The authors acknowledge the technical assistance of Elfriede Faber and the meticulous preparation of the manuscript by Tanja Loch. The study was supported by the Deutsche Forschungsgemeinschaft, DFG 315/15-1, to FL, and the Open Access Publishing Fund of Tuebingen University.

References

- 1 Takeshita K, Fujimori T, Kurotaki Y, Honjo H, Tsujikawa H, Yasui K, Lee JK, Kamiya K, Kitaichi K, Yamamoto K, Ito M, Kondo T, Iino S, Inden Y, Hirai M, Murohara T, Kodama I, Nabeshima Y: Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. *Circulation* 2004;109:1776-1782.
- 2 Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y: Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. *Mol Endocrinol* 2003;17:2393-2403.
- 3 Kuro-o M: Klotho. *Pflugers Arch* 2010;459:333-343.
- 4 Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. *Nature* 1997;390:45-51.
- 5 Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T, Nabeshima Y: Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. *FEBS Lett* 2004;565:143-147.
- 6 Akasaka-Manyu K, Manyu H, Kizuka Y, Oka S, Endo T: alpha-Klotho mice demonstrate increased expression of the non-sulfated N-glycan form of the HNK-1 glyco-epitope in kidney tissue. *J Biochem* 2014;156:107-113.
- 7 Buendia P, Carracedo J, Soriano S, Madueno JA, Ortiz A, Martin-Malo A, Aljama P, Ramirez R: Klotho Prevents NFkappaB Translocation and Protects Endothelial Cell From Senescence Induced by Uremia. *J Gerontol A Biol Sci Med Sci* 2014, DOI 10.1093/gerona/glu170.
- 8 Kuro-o M: Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. *Nat Rev Nephrol* 2013;9:650-660.
- 9 Razzaque MS, Sitara D, Taguchi T, St-Arnaud R, Lanske B: Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. *FASEB J* 2006;20:720-722.
- 10 Yoshida T, Fujimori T, Nabeshima Y: Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. *Endocrinology* 2002;143:683-689.
- 11 Ramasamy I: Recent advances in physiological calcium homeostasis. *Clin Chem Lab Med* 2006;44:237-273.
- 12 Zehnder D, Hewison M: The renal function of 25-hydroxyvitamin D3-1alpha-hydroxylase. *Mol Cell Endocrinol* 1999;151:213-220.
- 13 Heine G, Niesner U, Chang HD, Steinmeyer A, Zugel U, Zuberbier T, Radbruch A, Worm M: 1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells. *Eur J Immunol* 2008;38:2210-2218.
- 14 Hewison M, Freeman L, Hughes SV, Evans KN, Bland R, Eliopoulos AG, Kilby MD, Moss PA, Chakraverty R: Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. *J Immunol* 2003;170:5382-5390.
- 15 Hewison M, Kantorovich V, Liker HR, Van Herle AJ, Cohan P, Zehnder D, Adams JS: Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. *J Bone Miner Res* 2003;18:579-582.
- 16 Alesutan I, Feger M, Pakladok T, Mia S, Ahmed MS, Voelkl J, Lang F: 25-hydroxyvitamin d3 1-alpha-hydroxylase-dependent stimulation of renal klotho expression by spironolactone. *Kidney Blood Press Res* 2013;37:475-487.

- 17 Takenaka T, Inoue T, Ohno Y, Miyazaki T, Nishiyama A, Ishii N, Suzuki H: Calcitriol Supplementation Improves Endothelium-Dependent Vasodilation in Rat Hypertensive Renal Injury. *Kidney Blood Press Res* 2014;39:17-27.
- 18 Segawa H, Yamanaka S, Ohno Y, Onitsuka A, Shiozawa K, Aranami F, Furutani J, Tomoe Y, Ito M, Kuwahata M, Imura A, Nabeshima Y, Miyamoto K: Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice. *Am J Physiol Renal Physiol* 2007;292:F769-779.
- 19 Kuro-o M: Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. *Curr Opin Nephrol Hypertens* 2006;15:437-441.
- 20 Ohnishi M, Nakatani T, Lanske B, Razzaque MS: Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. *Kidney Int* 2009;75:1166-1172.
- 21 Anour R, Andrukhova O, Ritter E, Zeitz U, Erben RG: Klotho lacks a vitamin D independent physiological role in glucose homeostasis, bone turnover, and steady-state PTH secretion in vivo. *PLoS One* 2012;7:e31376.
- 22 Witkowski JM, Soroczynska-Cybula M, Bryl E, Smolenska Z, Jozwik A: Klotho--a common link in physiological and rheumatoid arthritis-related aging of human CD4+ lymphocytes. *J Immunol* 2007;178:771-777.
- 23 Boros S, Bindels RJ, Hoenderop JG: Active Ca(2+) reabsorption in the connecting tubule. *Pflugers Arch* 2009;458:99-109.
- 24 Cha SK, Hu MC, Kurosu H, Kuro-o M, Moe O, Huang CL: Regulation of renal outer medullary potassium channel and renal K(+) excretion by Klotho. *Mol Pharmacol* 2009;76:38-46.
- 25 Dermaku-Sopjani M, Sopjani M, Saxena A, Shojafard M, Bogatikov E, Alesutan I, Eichenmuller M, Lang F: Downregulation of NaPi-IIa and NaPi-IIb Na-coupled phosphate transporters by coexpression of Klotho. *Cell Physiol Biochem* 2011;28:251-258.
- 26 Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, Razzaque MS, Rosenblatt KP, Baum MG, Kuro-o M, Moe OW: Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. *FASEB J* 2010;24:3438-3450.
- 27 Sopjani M, Alesutan I, Dermaku-Sopjani M, Gu S, Zelenak C, Munoz C, Velic A, Foller M, Rosenblatt KP, Kuro-o M, Lang F: Regulation of the Na+/K+ ATPase by Klotho. *FEBS Lett* 2011;585:1759-1764.
- 28 Jan LY, Jan YN: Voltage-gated potassium channels and the diversity of electrical signalling. *J Physiol* 2012;590:2591-2599.
- 29 Ko EA, Park WS, Firth AL, Kim N, Yuan JX, Han J: Pathophysiology of voltage-gated K+ channels in vascular smooth muscle cells: modulation by protein kinases. *Prog Biophys Mol Biol* 2010;103:95-101.
- 30 Pongs O: Ins and outs of cardiac voltage-gated potassium channels. *Curr Opin Pharmacol* 2009;9:311-315.
- 31 Vacher H, Trimmer JS: Diverse roles for auxiliary subunits in phosphorylation-dependent regulation of mammalian brain voltage-gated potassium channels. *Pflugers Arch* 2011;462:631-643.
- 32 Comes N, Bielanska J, Vallejo-Gracia A, Serrano-Albarras A, Marruecos L, Gomez D, Soler C, Condom E, Ramon YCS, Hernandez-Losa J, Ferreres JC, Felipe A: The voltage-dependent K channels Kv1.3 and Kv1.5 in human cancer. *Front Physiol* 2013;4:283.
- 33 Szabo I, Zoratti M, Gulbins E: Contribution of voltage-gated potassium channels to the regulation of apoptosis. *FEBS Lett* 2010;584:2049-2056.
- 34 Cahalan MD, Chandy KG: The functional network of ion channels in T lymphocytes. *Immunol Rev* 2009;231:59-87.
- 35 Wang J, Xiang M: Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment? *Pharmacotherapy* 2013;33:515-528.
- 36 Choi BH, Hahn SJ: Kv1.3: a potential pharmacological target for diabetes. *Acta Pharmacol Sin* 2010;31:1031-1035.
- 37 Mahaut-Smith MP: The unique contribution of ion channels to platelet and megakaryocyte function. *J Thromb Haemost* 2012;10:1722-1732.
- 38 Henke G, Maier G, Wallisch S, Boehmer C, Lang F: Regulation of the voltage gated K+ channel Kv1.3 by the ubiquitin ligase Nedd4-2 and the serum and glucocorticoid inducible kinase SGK1. *J Cell Physiol* 2004;199:194-199.
- 39 Alesutan I, Sopjani M, Dermaku-Sopjani M, Munoz C, Voelkl J, Lang F: Upregulation of Na-coupled glucose transporter SGLT1 by Tau tubulin kinase 2. *Cell Physiol Biochem* 2012;30:458-465.

- 40 Henrion U, Zumhagen S, Steinke K, Strutz-Seebohm N, Stallmeyer B, Lang F, Schulze-Bahr E, Seebohm G: Overlapping cardiac phenotype associated with a familial mutation in the voltage sensor of the KCNQ1 channel. *Cell Physiol Biochem* 2012;29:809-818.
- 41 Pathare G, Foller M, Daryadel A, Mutig K, Bogatikov E, Fajol A, Almilaji A, Michael D, Stange G, Voelkl J, Wagner CA, Bachmann S, Lang F: OSR1-sensitive renal tubular phosphate reabsorption. *Kidney Blood Press Res* 2012;36:149-161.
- 42 Warsi J, Dong L, Elvira B, Salker MS, Shumilina E, Hosseinzadeh Z, Lang F: SPAK Dependent Regulation of Peptide Transporters PEPT1 and PEPT2. *Kidney Blood Press Res* 2014;39:388-398.
- 43 Almilaji A, Munoz C, Hosseinzadeh Z, Lang F: Upregulation of Na⁺,Cl⁻-coupled betaine/gamma-amino-butyric acid transporter BGT1 by Tau tubulin kinase 2. *Cell Physiol Biochem* 2013;32:334-343.
- 44 Dermaku-Sopjani M, Almilaji A, Pakladok T, Munoz C, Hosseinzadeh Z, Blecua M, Sopjani M, Lang F: Down-regulation of the Na⁺-coupled phosphate transporter NaPi-IIa by AMP-activated protein kinase. *Kidney Blood Press Res* 2013;37:547-556.
- 45 Hosseinzadeh Z, Bhavsar SK, Lang F: Down-regulation of the myoinositol transporter SMIT by JAK2. *Cell Physiol Biochem* 2012;30:1473-1480.
- 46 Warsi J, Hosseinzadeh Z, Elvira B, Bissinger R, Shumilina E, Lang F: Regulation of ClC-2 Activity by SPAK and OSR1. *Kidney Blood Press Res* 2014;39:378-387.
- 47 Bogatikov E, Munoz C, Pakladok T, Alesutan I, Shojaiefard M, Seebohm G, Foller M, Palmada M, Bohmer C, Broer S, Lang F: Up-regulation of amino acid transporter SLC6A19 activity and surface protein abundance by PKB/Akt and PIKfyve. *Cell Physiol Biochem* 2012;30:1538-1546.
- 48 Elvira B, Munoz C, Borrás J, Chen H, Warsi J, Ajay SS, Shumilina E, Lang F: SPAK and OSR1 Dependent Down-Regulation of Murine Renal Outer Medullary K Channel ROMK1. *Kidney Blood Press Res* 2014;39:353-360.
- 49 Hosseinzadeh Z, Dong L, Bhavsar SK, Warsi J, Almilaji A, Lang F: Upregulation of peptide transporters PEPT1 and PEPT2 by Janus kinase JAK2. *Cell Physiol Biochem* 2013;31:673-682.
- 50 Munoz C, Pakladok T, Almilaji A, Elvira B, Decher N, Shumilina E, Lang F: Up-regulation of Kir2.1 (KCNJ2) by the serum & glucocorticoid inducible SGK3. *Cell Physiol Biochem* 2014;33:491-500.
- 51 Hosseinzadeh Z, Bhavsar SK, Lang F: Downregulation of ClC-2 by JAK2. *Cell Physiol Biochem* 2012;29:737-742.
- 52 Mia S, Munoz C, Pakladok T, Siraskar G, Voelkl J, Alesutan I, Lang F: Downregulation of Kv1.5 K channels by the AMP-activated protein kinase. *Cell Physiol Biochem* 2012;30:1039-1050.
- 53 Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. *Pflugers Arch* 1981;391:85-100.
- 54 Almilaji A, Munoz C, Pakladok T, Alesutan I, Feger M, Foller M, Lang UE, Shumilina E, Lang F: Klotho sensitivity of the neuronal excitatory amino acid transporters EAAT3 and EAAT4. *PLoS One* 2013;8:e70988.
- 55 Almilaji A, Szteyn K, Fein E, Pakladok T, Munoz C, Elvira B, Towhid ST, Alesutan I, Shumilina E, Bock CT, Kandolf R, Lang F: Down-regulation of Na/K⁺ atpase activity by human parvovirus B19 capsid protein VP1. *Cell Physiol Biochem* 2013;31:638-648.
- 56 Pakladok T, Almilaji A, Munoz C, Alesutan I, Lang F: PIKfyve sensitivity of hERG channels. *Cell Physiol Biochem* 2013;31:785-794.
- 57 Szteyn K, Schmid E, Nurbaeva MK, Yang W, Munzer P, Kunzelmann K, Lang F, Shumilina E: Expression and functional significance of the Ca²⁺-activated Cl⁻ channel ANO6 in dendritic cells. *Cell Physiol Biochem* 2012;30:1319-1332.
- 58 Barry PH, Lynch JW: Liquid junction potentials and small cell effects in patch-clamp analysis. *J Membr Biol* 1991;121:101-117.
- 59 Szabo I, Gulbins E, Apfel H, Zhang X, Barth P, Busch AE, Schlottmann K, Pongs O, Lang F: Tyrosine phosphorylation-dependent suppression of a voltage-gated K⁺ channel in T lymphocytes upon Fas stimulation. *J Biol Chem* 1996;271:20465-20469.
- 60 Honore E, Attali B, Romey G, Lesage F, Barhanin J, Lazdunski M: Different types of K⁺ channel current are generated by different levels of a single mRNA. *EMBO J* 1992;11:2465-2471.
- 61 Hu MC, Kuro-o M, Moe OW: Klotho and chronic kidney disease. *Contrib Nephrol* 2013;180:47-63.
- 62 Huang CL: Regulation of ion channels by secreted Klotho. *Adv Exp Med Biol* 2012;728:100-106.

- 63 Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro OM, Huang CL: Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. *Proc Natl Acad Sci USA* 2008;105:9805-9810.
- 64 Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG: The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. *Science* 2005;310:490-493.
- 65 Leunissen EH, Nair AV, Bull C, Lefeber DJ, van Delft FL, Bindels RJ, Hoenderop JG: The epithelial calcium channel TRPV5 is regulated differentially by klotho and sialidase. *J Biol Chem* 2013;288:29238-29246.
- 66 Lu P, Boros S, Chang Q, Bindels RJ, Hoenderop JG: The beta-glucuronidase klotho exclusively activates the epithelial Ca²⁺ channels TRPV5 and TRPV6. *Nephrol Dial Transplant* 2008;23:3397-3402.
- 67 Almilaji A, Pakladok T, Munoz C, Elvira B, Sopjani M, Lang F: Upregulation of KCNQ1/KCNE1 K channels by Klotho. *Channels (Austin)* 2014;8, in press.
- 68 Munoz C, Pakladok T, Almilaji A, Elvira B, Seeböhm G, Voelkl J, Foller M, Shumilina E, Lang F: Klotho sensitivity of the hERG channel. *FEBS Lett* 2013;587:1663-1668.
- 69 Kusaba T, Okigaki M, Matui A, Murakami M, Ishikawa K, Kimura T, Sonomura K, Adachi Y, Shibuya M, Shirayama T, Tanda S, Hatta T, Sasaki S, Mori Y, Matsubara H: Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca²⁺ channel to maintain endothelial integrity. *Proc Natl Acad Sci USA* 2010;107:19308-19313.
- 70 Feger M, Fajol A, Lebedeva A, Meissner A, Michael D, Voelkl J, Alesutan I, Schleicher E, Reichetzeder C, Hoher B, Qadri SM, Lang F: Effect of carbon monoxide donor CORM-2 on vitamin D3 metabolism. *Kidney Blood Press Res* 2013;37:496-505.
- 71 Abed M, Feger M, Alzoubi K, Pakladok T, Frauenfeld L, Geiger C, Towhid ST, Lang F: Sensitization of erythrocytes to suicidal erythrocyte death following water deprivation. *Kidney Blood Press Res* 2013;37:567-578.
- 72 Shumilina E, Nurbaeva MK, Yang W, Schmid E, Sztejn K, Russo A, Heise N, Leibrock C, Xuan NT, Faggio C, Kuro-o M, Lang F: Altered regulation of cytosolic Ca²⁺(+) concentration in dendritic cells from klotho hypomorphic mice. *Am J Physiol Cell Physiol* 2013;305:C70-77.
- 73 Kido S, Kaneko I, Tatsumi S, Segawa H, Miyamoto K: Vitamin D and type II sodium-dependent phosphate cotransporters. *Contrib Nephrol* 2013;180:86-97.
- 74 Boyan BD, Schwartz Z, Carnes DL, Jr., Ramirez V: The effects of vitamin D metabolites on the plasma and matrix vesicle membranes of growth and resting cartilage cells in vitro. *Endocrinology* 1988;122:2851-2860.
- 75 Christakos S, Dhawan P, Ajibade D, Benn BS, Feng J, Joshi SS: Mechanisms involved in vitamin D mediated intestinal calcium absorption and in non-classical actions of vitamin D. *J Steroid Biochem Mol Biol* 2010;121:183-187.
- 76 Dawson PA, Markovich D: Transcriptional regulation of the sodium-sulfate cotransporter NaS(i)-1 gene. *Cell Biochem Biophys* 2002;36:175-182.
- 77 Meyer MB, Watanuki M, Kim S, Shevde NK, Pike JW: The human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells. *Mol Endocrinol* 2006;20:1447-1461.
- 78 Borst O, Munzer P, Schmid E, Schmidt EM, Russo A, Walker B, Yang W, Leibrock C, Sztejn K, Schmidt S, Elvers M, Faggio C, Shumilina E, Kuro OM, Gawaz M, Lang F: 1,25(OH)₂ vitamin D3-dependent inhibition of platelet Ca²⁺ signaling and thrombus formation in klotho-deficient mice. *FASEB J* 2014;28:2108-2119.
- 79 Orban C, Biro E, Grozdics E, Bajnok A, Toldi G: Modulation of T lymphocyte calcium influx patterns via the inhibition of kv1.3 and ikca1 potassium channels in autoimmune disorders. *Front Immunol* 2013;4:234.
- 80 Toldi G, Bajnok A, Dobi D, Kaposi A, Kovacs L, Vasarhelyi B, Balog A: The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis. *Immunobiology* 2013;218:311-316.
- 81 Matsubara T, Miyaki A, Akazawa N, Choi Y, Ra SG, Tanahashi K, Kumagai H, Oikawa S, Maeda S: Aerobic exercise training increases plasma Klotho levels and reduces arterial stiffness in postmenopausal women. *Am J Physiol Heart Circ Physiol* 2014;306:H348-355.
- 82 Pedersen L, Pedersen SM, Brasen CL, Rasmussen LM: Soluble serum Klotho levels in healthy subjects. Comparison of two different immunoassays. *Clin Biochem* 2013;46:1079-1083.